S7 Ep25: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Mutant NSCLC
Aug 25, 2022
11:10
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr Levy discusses the significance of the FDA approval of trastuzumab deruxtecan in HER2-mutant NSCLC, the pivotal efficacy and safety data from the DESTINY-Lung02 trial, and the optimal use of companion diagnostic tests in the field.
OncLive® On Air